Interestingly, reduction in fat mass and increase in TBW would keep the weight of the subjects neutral as seen in most trials with DPP4 inhibitors, however this may not be clinically relevant in subjects with no overt heart failure [16]. The gene discussed is DPP4; the disease is heart failure.